177 related articles for article (PubMed ID: 32950694)
1. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e335-e336. PubMed ID: 32950694
[No Abstract] [Full Text] [Related]
2. Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e333-e334. PubMed ID: 32950695
[No Abstract] [Full Text] [Related]
3. Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e122-e123. PubMed ID: 30036350
[No Abstract] [Full Text] [Related]
4. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
[TBL] [Abstract][Full Text] [Related]
5. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
7. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
Locke FL; Go WY; Neelapu SS
JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
[TBL] [Abstract][Full Text] [Related]
8. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
9. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
11. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Bouchkouj N; Kasamon YL; de Claro RA; George B; Lin X; Lee S; Blumenthal GM; Bryan W; McKee AE; Pazdur R
Clin Cancer Res; 2019 Mar; 25(6):1702-1708. PubMed ID: 30413526
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
14. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M
Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558
[No Abstract] [Full Text] [Related]
15. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M
Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539
[TBL] [Abstract][Full Text] [Related]
16. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
Ghafouri S; Timmerman J; Larson S; Mead MD
Bone Marrow Transplant; 2021 Apr; 56(4):974-977. PubMed ID: 33168933
[No Abstract] [Full Text] [Related]
17. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
19. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
Mian A; Wei W; Hamilton BK; Winter AM; Khouri J; Pohlman B; Gerds AT; Jagadeesh D; Anwer F; Kalaycio M; Dean RM; Sobecks R; Caimi PF; Hill BT; Majhail NS
Bone Marrow Transplant; 2023 May; 58(5):590-593. PubMed ID: 36774431
[No Abstract] [Full Text] [Related]
20. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
